Investing.comCodex · 实盘不做把握 4/10
北京时间·🕒 发布 08-04 21:04:42时区推断·⟳ 抓取 08-04 21:06:25·⚡ 决策 08-05 13:19:49 +16h13m·83.3 天前
ENvue Medical完成NanoVibronix制造业务迁至美国
制造迁回美国并整合研发理论上可降本提效，但公司未披露节省金额、毛利改善幅度或产能变化。
📄 原文Investing.com↗ 原文
ENvue Medical completes US manufacturing transition
BofA says this memory stock could double. Here are 5 reasons why TYLER, Texas - ENvue Medical, Inc. (NASDAQ:FEED) annou…
不做 ENvue Medical（FEED.US）
降本提效方向虽正面，但未披露成本节省或利润量级，且不是订单/批件类硬催化，不做
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 low · price-in 风险 medium ↗
关键理由
- 制造迁回美国并整合研发理论上可降本提效，但公司未披露节省金额、毛利改善幅度或产能变化。
主要风险
- 缺少量化成本节省，且微型医疗器械公司执行和流动性风险高。
原文全文
展开原文 · 1,663 字
BofA says this memory stock could double. Here are 5 reasons why
TYLER, Texas - ENvue Medical, Inc. (NASDAQ:FEED) announced today it has completed the relocation of its NanoVibronix manufacturing operations from Israel to the United States and consolidated its research and development operations in Tel Aviv, Israel, according to a press release statement.
The commercial-stage medical device company said the move is part of an initiative to reduce operating expenses and improve its cost structure. The company now manufactures its entire NanoVibronix product line domestically.
"By consolidating our manufacturing operations domestically, we expect to improve operational efficiency, reduce costs, and streamline supply chain management, while enhancing operational oversight as we continue to grow," said Doron Besser, CEO of ENvue Medical.
The NanoVibronix product line includes PainShield and UroShield, which use low-intensity surface acoustic wave technology and are designed for use in home or care settings.
ENvue Medical is a medical technology company headquartered in Tyler, Texas, with research and development operations in Tel Aviv, Israel. The company focuses on two technology platforms: the ENvue Navigation Platform, an electromagnetic navigation system cleared by the FDA for adult use to assist in placing feeding tubes, and acoustic-based therapeutic technologies including the NanoVibronix products.
The company’s devices are intended to treat pain, reduce bacterial colonization, and disrupt biofilms in home or care settings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TYLER, Texas - ENvue Medical, Inc. (NASDAQ:FEED) announced today it has completed the relocation of its NanoVibronix manufacturing operations from Israel to the United States and consolidated its research and development operations in Tel Aviv, Israel, according to a press release statement.
The commercial-stage medical device company said the move is part of an initiative to reduce operating expenses and improve its cost structure. The company now manufactures its entire NanoVibronix product line domestically.
"By consolidating our manufacturing operations domestically, we expect to improve operational efficiency, reduce costs, and streamline supply chain management, while enhancing operational oversight as we continue to grow," said Doron Besser, CEO of ENvue Medical.
The NanoVibronix product line includes PainShield and UroShield, which use low-intensity surface acoustic wave technology and are designed for use in home or care settings.
ENvue Medical is a medical technology company headquartered in Tyler, Texas, with research and development operations in Tel Aviv, Israel. The company focuses on two technology platforms: the ENvue Navigation Platform, an electromagnetic navigation system cleared by the FDA for adult use to assist in placing feeding tubes, and acoustic-based therapeutic technologies including the NanoVibronix products.
The company’s devices are intended to treat pain, reduce bacterial colonization, and disrupt biofilms in home or care settings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。